Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Ardelyx shares surged 12% following a CNBC-TV18 report that Indian pharmaceutical company Zydus Lifesciences is in active talks to acquire the company or potentially purchase selected assets.</li><li>While neither party confirmed the speculation, Zydus is reportedly exploring a qualified institutional placement to raise funds for the potential acquisition.</li><li>With Ardelyx currently valued at around $1.6 billion, any such transaction would mark a significant strategic move by Zydus, particularly given Ardelyx’s notable commercial traction in gastrointestinal and renal therapies.</li></ul>

Ardelyx shares surged 12% following a CNBC-TV18 report that Indian pharmaceutical company Zydus Lifesciences is in active talks to acquire the company or potentially purchase selected assets.While neither party confirmed the speculation, Zydus is reportedly exploring a qualified institutional placement to raise funds for the potential acquisition.With Ardelyx currently valued at around $1.6 billion, any such transaction would mark a significant strategic move by Zydus, particularly given Ardelyx’s notable commercial traction in gastrointestinal and renal therapies.

Ardelyx の展開: Zydus Lifesciences はゲームを変えるような買収を計画しているのか?

Ardelyx Inc

Ardelyx の展開: Zydus Lifesciences はゲームを変えるような買収を計画しているのか?